The synthesis of erythropoiesis-stimulating agents (ESAs), especially recombinant human erythropoietin, has provided a new therapeutic option for the treatment of patients with various forms of anemia, including that of chronic renal disease, malignancy, hematologic disorders, prematurity, and acquired immune deficiency syndrome. These agents are effective in improving the hematologic response and reducing the need for red blood cells transfusion, and they also appear to have a positive effect on some health-related quality-of-life indicators. The incidence of side effects and survival, however, remains highly uncertain, and several studies have recently highlighted the problem of an increased trend of tumor progression, mortality and throm...
Erythropoiesis-stimulating agents (ESAs) are effective drugs to correct and maintain haemoglobin (Hb...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Anemia is common in patients with cancer or with chronic kidney disease (CKD). Although the introduc...
Anaemia is one of the most significant factors that lead to deteriorated quality of life and limited...
Erythropoiesis stimulating agents have been used for more than a decade in patients with chronic kid...
Cancer patients often develop the potentially debilitating condition of anaemia. Numerous controlled...
Erythropoiesis-stimulating agents (ESAs) increase red blood cell (RBC) production in bone marrow by ...
Anemia associated with cancer and cancer therapy is a common and important issue in the treatment of...
Chemotherapy-induced anemia (CIA) is a frequent problem in cancer patients with a negative impact on...
Summary: The recombinant human erythropoietin (rHuEPO), an effective agent in the treatment of renal...
Erythropoietin is produced by the kidney and stimulates growth and differentiation of red blood cell...
Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagul...
We conducted a retrospective analysis of publicly available preclinical toxicology studies with eryt...
Purpose. With the emerging new warnings surrounding the use of erythropoiesis-stimulating agents (ES...
increase mortality and venous thrombo-embolism in cancer-associated anemia Bennett CL, Silver SM, Dj...
Erythropoiesis-stimulating agents (ESAs) are effective drugs to correct and maintain haemoglobin (Hb...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Anemia is common in patients with cancer or with chronic kidney disease (CKD). Although the introduc...
Anaemia is one of the most significant factors that lead to deteriorated quality of life and limited...
Erythropoiesis stimulating agents have been used for more than a decade in patients with chronic kid...
Cancer patients often develop the potentially debilitating condition of anaemia. Numerous controlled...
Erythropoiesis-stimulating agents (ESAs) increase red blood cell (RBC) production in bone marrow by ...
Anemia associated with cancer and cancer therapy is a common and important issue in the treatment of...
Chemotherapy-induced anemia (CIA) is a frequent problem in cancer patients with a negative impact on...
Summary: The recombinant human erythropoietin (rHuEPO), an effective agent in the treatment of renal...
Erythropoietin is produced by the kidney and stimulates growth and differentiation of red blood cell...
Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagul...
We conducted a retrospective analysis of publicly available preclinical toxicology studies with eryt...
Purpose. With the emerging new warnings surrounding the use of erythropoiesis-stimulating agents (ES...
increase mortality and venous thrombo-embolism in cancer-associated anemia Bennett CL, Silver SM, Dj...
Erythropoiesis-stimulating agents (ESAs) are effective drugs to correct and maintain haemoglobin (Hb...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Anemia is common in patients with cancer or with chronic kidney disease (CKD). Although the introduc...